|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:2040-2044, doi:10.1016/j.jacc.2007.10.069 © 2008 by the American College of Cardiology Foundation |



* Cardio-Metabolic Unit and the Centre for Applied Clinical Research (Ce.R.C.A.) Clinical Institute "Beato Matteo," Hospital Group San Donato, Vigevano, Italy
Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy
Diabetes Centre, A.O. Province of Pavia, Pavia, Italy
Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy
|| Endocrinology Unit, University of Brescia, Brescia, Italy.
Manuscript received June 18, 2007; revised manuscript received October 9, 2007, accepted October 15, 2007.
* Reprint requests and correspondence: Dr. Carmine Gazzaruso, Clinical Institute "Beato Matteo," Via Aselli, 5, 27100 Pavia, Italy. (Email: c.gazzaruso{at}tele2.it).
Objectives: We sought to investigate whether erectile dysfunction (ED) is a predictor of future cardiovascular events and death in diabetic patients with silent coronary artery disease (CAD) and whether there are predictors of cardiovascular events and death among CAD diabetic patients with ED.
Background: Case-control studies showed that ED is associated with CAD in diabetic patients, but no prospective study is available.
Methods: Type 2 diabetic men (n = 291) with silent CAD angiographically documented were recruited. Erectile dysfunction was assessed by the International Index Erectile Function-5 questionnaire.
Results: During a follow-up period of 47.2 ± 21.8 months (range 4 to 82 months), 49 patients experienced major adverse cardiac events (MACE). The difference in ED prevalence between patients with and those without MACE was significant (61.2% vs. 36.4%; p = 0.001). Cox regression analysis showed that ED predicted MACE (hazard ratio [HR] 2.1; 95% confidence interval [CI] 1.6 to 2.6; p < 0.001). Among patients with CAD and ED, the Kaplan-Meier method showed that the statin (Mantel log-rank test: 3.921; p = 0.048) and 5-phosphodiesterase (5-PDE) inhibitor use (Mantel log-rank test: 4.608; p = 0.032) were associated with a lower rate of MACE. Cox regression analysis showed that statin use (HR 0.66; 95% CI 0.46 to 0.97; p = 0.036) reduced MACE. Treatment with 5-PDE inhibitors did not enter the model, but its p value was very near to the significant level (HR 0.68; 95% CI 0.46 to 1.01; p = 0.056).
Conclusions: Our data first show that ED is a powerful predictor of cardiovascular morbidity and mortality in diabetic patients with silent CAD and that the treatment with statins and 5-PDE inhibitors might reduce the occurrence of MACE among CAD diabetic patients with ED.
| ||||||||||
Related Articles
J. Am. Coll. Cardiol. 2008 51: 2051-2052.
J. Am. Coll. Cardiol. 2008 51: A23-A24.
This article has been cited by other articles:
![]() |
Erectile Dysfunction: A New Risk Factor for Heart Disease Journal Watch Cardiology, June 25, 2008; 2008(625): 4 - 4. [Full Text] |
||||
![]() |
R. A. Kloner Erectile Dysfunction: The New Harbinger for Major Adverse Cardiac Events in the Diabetic Patient J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2051 - 2052. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |